Physician profile
Abdul Dada
NPI 1376036970
$3,727.51
in general payments reported to CMS, 2019-2025
24 companies · $93.31 in 2025
The $93.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $2,104 · 2024: $1,330 · 2025: $93.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763 · Travel and Lodging: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.71 |
| Travel and Lodging | $764.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,313.79 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $940.64 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $211.84 | 2022-2024 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.92 | 2023-2024 | Caplyta |
| Novo Nordisk INC | $152.26 | 2023-2024 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $120.76 | 2023-2024 | |
| Mylan Specialty L.P. | $86.93 | 2024 | Yupelri |
| Exact Sciences Corporation | $86.02 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.84 | 2022-2024 | Xifaxan |
| Boston Scientific Corporation | $72.15 | 2023-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Bayer Healthcare Pharmaceuticals INC. | $69.86 | 2024 | |
| Lilly USA, LLC | $69.65 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $64.57 | 2022-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $41.18 | 2024 | |
| Ethicon INC. | $41.12 | 2023 | Monarch Platform |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.58 | 2022-2024 | Otezla, Repatha |
| Dexcom, INC. | $37.46 | 2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $24.05 | 2024 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $19.75 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $19.52 | 2023 | Pneumovax 23, Gardasil 9, M-M-R II |
| Novartis Pharmaceuticals Corporation | $17.28 | 2023 | |
| Abbott Laboratories | $16.41 | 2023 | Freestyle Libre 3 |
| Biogen, INC. | $15.68 | 2024 | Skyclarys |
| Sumitomo Pharma America, INC. | $14.25 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Dada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.